These results showed that cardiac hypertrophy and myocardial collagen deposition were considerably reduced by the combination of ADAM17 knockdown and eplerenone treatment compared with single therapy with ADAM17 deficiency or eplerenone administration. The gene discussed is ADAM17; the disease is cardiac hypertrophy.